Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 2 months ago

Indications

Doriject is used to treat the following infections. Complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus, and Peptostreptococcus micros. Complicated urinary tract infections, including pyelonephritis, caused by Escherichia coli (including cases with concurrent bacteremia), Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Doripenem is a broad-spectrum carbapenem class of antibacterial with activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria.Doripenem exerts its bactericidal activity by inhibiting bacterial cell wall biosynthesis. Doripenem inactivates multiple essential penicillin-binding proteins (PBPs) resulting in inhibition of cell wall synthesis with subsequent cell death. In E. coli and P. aeruginosa,Doripenem binds to PBP 2, which involved in the maintenance of cell shape, as well as to PBPs 3 and 4.Absorption: Mean plasma concentrations of Doripenem following a single 1-hour intravenous infusion of a 500 mg dose to 24 healthy subjects is 23.0 (6.6) pg/mL. The pharmacokinetics of Doripenem (Cmax and AUC) are linear over a dose range of 500 mg to 1 g when intravenously infused over 1 hour. There is no accumulation of Doripenem following multiple intravenous infusions of either 500 mg or 1 g administered every 8 hours for 7 to 10 days in subjects with normal renal function.Distribution: The average binding of Doripenem to plasma proteins is approximately 8.1% and is independent of plasma drug concentrations. The median (range) volume of distribution at steady state in healthy subjects is 16.8 L (8.09-55.5 L), similar to extracellular fluid volume (18.2 L).Metabolism: Metabolism of doripenem to a microbiologically inactive ring-opened metabolite (doripenem-M1) occurs primarily via dehydropeptidase-l. In pooled human liver microsomes, no in vitro metabolism of Doripenem could be detected, indicating that Doripenem is not a substrate for hepatic CYP450 enzymes.Excretion: Doripenem is primarily eliminated unchanged by the kidneys. The mean plasma terminal elimination half-life of Doripenem in healthy non-elderly adults is approximately 1 hour and mean (SD) plasma clearance is 15.9 (5.3) L/hour. Mean renal clearance is 10.8 (3.5) L/hour. In healthy adults given a single 500 mg dose a mean of 70% and 15% of the dose was recovered in urine as unchanged drug and the ring-opened metabolite, respectively, within 48 hours.

Pregnancy & Breastfeeding

Pregnancy Category B. Well-controlled studies in pregnant women have not been done, and because animal studies don't always predict how humans will respond, Doripenem should be used in pregnancy only when clearly necessary. Whether it passes into human breast milk isn't known, but since many drugs do, a nursing mother should use it with caution.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Dosage The recommended dosage of Doripenem is 500 mg given every 8 hours by intravenous infusion over one hour in patients over 18 years of age. For complicated intra abdominal infection, the dose is 500 mg every 8 hours for 5 to 14 days, infused over 1 hour. For complicated UTI, including pyelonephritis, the dose is 500 mg every 8 hours for 10 days, infused over 1 hour. Dosage of Doripenem in patients with renal impairment: for CrCl above 50 mL/min, no dosage adjustment is necessary. For CrCl from 30 to 50 mL/min, the dose is 250 mg given intravenously over 1 hour every 8 hours. For CrCl above 10 and below 30 mL/min, the dose is 250 mg given intravenously over 1 hour every 12 hours. Geriatric patients: no dosage adjustment is recommended for elderly patients with normal (for their age) renal function.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.

Key Interactions

Checker →